前不久,知名单分子免疫检测公司Quanterix宣布其Simoa磷酸化Tau217(p-Tau217)血液检测产品已被美国FDA授予"突破性器械 "认证,可用于阿尔茨海默氏症的辅助诊断。随后,Roche的Elecsys p-Tau217血浆生物标志物检测产品也获得该认证。 而在上周,金域医学联合知名医院,建立了中国人群参考值范围,推出了p-Tau217单分子免疫检测。
现在,基于这种有前景的生物标志物pTau217的循环水平,一种创新的血液测试可以用于AD的筛查、诊断和监测。 ALZpath-Dx(美国加利福尼亚州卡尔斯巴德)利用专有的单克隆pTau217抗体和肽校准器,开发了一种强大且可扩展的基于血浆的超灵敏测定法,品牌为ALZpathDx。这种基于血液的ELISA测定是在半自动单分子阵列(Simoa)平台...
In March 2022, Quanterix firstannouncedits entry into license and collaboration agreements with Lilly, which specified the initial development of a test for the Eli Lilly Clinical Diagnostics Laboratory (ELCDL), a wholly owned subsidiary of Lilly. Now, with the Simoa® p-Tau 217 Planar Kit, ...
日前,礼来研究人员在11月初举行的阿尔茨海默症临床试验(CTAD)会议上表示,公司旗下研究的磷酸化tau(P-tau)生物标志物检测方法有望实现更早期、更准确的检测。为此,礼来及其致力于发现和开发放射性药物和影像学方法的全资子公司Avid Radiopharmaceuticals正在进行P-tau217作为AD病理生物标志物的研究。 礼来的高级研究顾问Je...
LucentAD, p-Tau 217 Blood-Based Biomarker (BBM) Test LucentAD p-Tau 217 is a non-invasive blood test to help identify if a patient with cognitive impairment symptoms is likely or unlikely to have amyloid plaques in the brain, a hallmark of Alzheimer’s Disease. LucentAD p-Tau 217 relies...
The performance of plasma p-tau217 was significantly better for detection of Aβ pathology compared to T pathology (DeLong test, z = 1.75, p = 0.04). Of note, there were no significant differences between Aβ—T + and Aβ—T- participants or between Aβ + T- and ...
A blood test that measures plasma tau phosphorylated at threonine 217 (P-tau217) can accurately distinguish Alzheimer's disease (AD) from other neurodegenerative disorders, new research suggests. Results from a large multinational study showed that the level of P-tau217 in blood collected during ...
Plasma p-tau217 was nearly 4-fold higher in Aβ+ (13.89; 7.36-19.0pg/mL) vs Aβ- (3.72; 2.80-4.09pg/mL, U = 230, p<0.001) participants. Plasma p-tau217 was superior in the identification of Aβ vs T pathology (p<0.05, DeLong Test) and outperformed p-tau181 and other BBMs(...
14. Moreover, plasma p-tau217 is strongly associated with measures of Aβ pathology and its levels change before tau-PET abnormalities are detectable in AD progression15,16,17, making it a feasible candidate to implement as a routine clinical chemistry test to screen for Aβ positivity in ...
, the highest AUCs were reached by plasma Aβ42/40 (AUC = 0.750 (95% confidence interval (CI) = 0.702–0.798)) and p-tau231 (AUC = 0.740 (95% CI = 0.688–0.793)). DeLong’s test revealed that plasma biomarkers performed similarly well, with only plasma p-tau231...